BiotechTube

AFQ056 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cocaine-related Disorder

Conditions

Cocaine-related Disorder

Trial Timeline

Dec 4, 2017 → Dec 16, 2019

NCT ID
NCT03242928

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Cocaine-related Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03242928. Target conditions include Cocaine-related Disorder.

What happened to similar drugs?

1 of 2 similar drugs in Cocaine-related Disorder were approved

Approved (1) Terminated (0) Active (1)
✅quetiapineAstraZenecaApproved
🔄Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT04771143Phase 1Withdrawn
NCT03242928Phase 2Completed
NCT02920892Phase 2Completed
NCT01813019Phase 2Terminated
NCT01491529Phase 2Completed
NCT01385592Phase 2Completed
NCT01357239Phase 2Completed
NCT01253629Phase 2Completed
NCT01019473Phase 2Terminated
NCT00888004Phase 2Completed
NCT00582673Phase 2Completed

Competing Products

3 competing products in Cocaine-related Disorder

See all competitors
ProductCompanyStageHype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
36
TopiramateJohnson & JohnsonPhase 2
35
quetiapineAstraZenecaApproved
43